Results 91 to 100 of about 20,432 (139)

Therapeutic strategies in prion disease: current evidence, translational challenges, and emerging directions. [PDF]

Front Neurosci
Zhu Y, Bradford BM, Mabbott NA.
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens. [PDF]

Pharmaceutics
Chen L, Wang X, Li L, Yang Y, Liu Y, Chen W.   +5 more
europepmc   +1 more source

Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: A target trial emulation. [PDF]

Ann Epidemiol
Zheng A, Fox MP, Greener R, Kileel EM, Bor J, Venter WD, Pisa PT, Murray EJ, Brennan AT, Maskew M.   +9 more
europepmc   +1 more source

Virologic Outcomes of Common First-Line Antiretroviral Regimens Among Adults with HIV - China, 2021-2023. [PDF]

China CDC Wkly
Jia H, Zhao Y, Guan Y, Liu J, Geng Y, Gan X, Liu Y.   +6 more
europepmc   +1 more source

Clinical and demographic characteristics of adult patients experiencing virologic failure on antiretroviral therapy in the Blouberg sub-district, South Africa. [PDF]

BMC Infect Dis
Mulaisi TE, Raliphaswa NS.
europepmc   +1 more source

Kidney function parameters in South African children living with HIV on antiretroviral therapy. [PDF]

Antivir Ther
Shen Y, Huang EY, Yin O, Shiau S, Strehlau R, Patel F, Kuhn L, Lin F, Arpadi SM.   +8 more
europepmc   +1 more source

Analysis of HIV Drug Resistance Mutations Along With Treatment Outcomes of Efavirenz-Based Regimens in Patients With V179D/E Mutations in Guangzhou, China. [PDF]

Can J Infect Dis Med Microbiol
Zheng X, Xiao Y, Zhang Y, Wang P, Zhang Y, Li L, Zheng Y, Li X, Chen D, Yang X, Huang Z.   +10 more
europepmc   +1 more source

A Physiologically Based Pharmacokinetic Model to Predict Potential Drug-Drug Interactions of TPN171, a Novel Phosphodiesterase Type 5 Inhibitor. [PDF]

CPT Pharmacometrics Syst Pharmacol
Tian G, Chen T, Li L, Wang Z, Yang H, Juan J, Duan Y, Pei J, Jia J.   +8 more
europepmc   +1 more source

Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial. [PDF]

Lancet Reg Health Southeast Asia
Kajeekul R, Ruenroengbun N, Wiwatrojanagul S, Kirdtongkum K, Chantaranothai W, Bin Khalid KE, Sirijatuphat R, Ngamprasertchai T.   +7 more
europepmc   +1 more source

Therapeutic Failure or Success Risk Associated With the Dynamic of Immunological Parameters in People Living With HIV-1 on Antiretroviral Treatment in Benin. [PDF]

AIDS Res Treat
Assogba YP, Nouatin OP, Tchiakpe E, Adechina AP, Fachinan RA, Adegnika RM, Adjou ES, Diop-Ndiaye H, Bankole HS, Yessoufou A.   +9 more
europepmc   +1 more source